EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions

Rajkamal Srivastava iD, Cammie F Lesser iD

Microbial Biotechnology · 2024-11 · 17 (11)

DOI: 10.1111/1751-7915.70057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 23.11.2024. Verfasst von Rajkamal Srivastava und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, US…. Hauptthemen laut MEDLINE: Bacteria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Live biotherapeutic products (LBPs), including engineered bacteria, are rapidly emerging as potential therapeutic interventions. These innovative therapies can serve as live in situ drug delivery platforms for the direct deposition of therapeutic payloads, including complex biologics, at sites of disease. This approach offers a platform likely to enhance therapeutic efficacy and decrease off‐target side effects. LBPs also can likely be distributed at a relatively low price point, as their production can be economically scaled up. LBPs represent an exciting new means for ensuring healthy lives and promoting well‐being for all ages, aligning with the World Health Organization's sustainable development goal 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteriaHumansBiological ProductsDrug Delivery SystemsBiological TherapyMicroorganisms, Genetically-Modified

Stichwörter der Autor:innen

engineered bacterialive biotherapeutic productssmart microbes

Substanzen

Biological Products

Autor:innen und Institutionen

  • Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Ragon Institute of Harvard and MIT, Cambridge, Massachusetts, USA.

ORCID-Profile: Rajkamal Srivastava, Cammie F Lesser

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIDDK NIH HHS
  • the Brit d'Arbeloff Research Scholar award
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Cancer Institute

Zitieren

APA

Srivastava, R., & Lesser, C. F. (2024). Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions. Microbial Biotechnology, 17(11). https://doi.org/10.1111/1751-7915.70057

Vancouver

Srivastava R, Lesser CF. Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions. Microbial Biotechnology. 2024;17(11). doi:10.1111/1751-7915.70057

BibTeX
@article{Srivastava2024,
  author = {Srivastava, Rajkamal and Lesser, Cammie F},
  title = {Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions},
  journal = {Microbial Biotechnology},
  year = {2024},
  volume = {17},
  number = {11},
  doi = {10.1111/1751-7915.70057}
}
Kostenlos starten →